专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2020130948A1 METHOD OF PREDICTING FOR BENEFIT FROM IMMUNE CHECKPOINT INHIBITION THERAPY 审中-公开
公开(公告)号：WO2020130948A1
公开(公告)日：2020-06-25
申请号：PCT/SG2019/050629
申请日：2019-12-20
申请人： AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH , NATIONAL UNIVERSITY HOSPITAL (SINGAPORE) PTE LTD , NATIONAL UNIVERSITY OF SINGAPORE
发明人： TAN, Patrick , SUNDAR, Raghav , HUANG, Kie Kyon , QAMRA, Aditi , GOKE, Jonathan , DEMIRCIOGLU, Deniz
IPC分类号： C12Q1/68 , A61K39/395 , A61P35/00
摘要： The present invention relates to a method of identifying a cancer patient as benefiting or not benefiting from immune checkpoint inhibition therapy comprising measuring an expression level of one or more preselected markers in a cancerous biological sample obtained from the patient, identifying a differentially expressed alternative promoter based on the expression level of the one or more preselected markers, calculating an alternative promoter usage score (APB score) and identifying the patient as benefiting or not benefiting from immune checkpoint inhibition therapy using the APB score. In particular, patients with high APB score has lower expression of CD8A, granzyme A and perforin 1 and have worse progression-free survival than patients with low APB score. Patients with lower APB score have higher objective response rate as compared to patients with APB score.

2. 发明申请

WO2015142293A1 FUSION GENES IN CANCER 审中-公开
标题翻译：癌症融合基因
公开(公告)号：WO2015142293A1
公开(公告)日：2015-09-24
申请号：PCT/SG2015/050047
申请日：2015-03-23
申请人： AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH , NATIONAL UNIVERSITY OF SINGAPORE
发明人： HILLMER, Axel , RUAN, Yijun , YAO, Fei , TAN, Patrick , YEOH, Khay Guan , HUNZIKER, Walter , TEO, Audrey S M , SIA, Yee Yen
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156
摘要： The present invention relates to a method for determining or making of a prognosis if a patient has cancer or is at an increased risk of having cancer, the method comprising testing for the presence of one or more cancer-associated fusion genes, or proteins derived thereof, in a sample obtained from a patient. More specifically, the present invention relates to fusion genes CLEC16A-EMP2, SNX2-PRDM6, MLL3-PRKAG2, DUS2L-PSKH1 and CLDN18- ARHGAP26 in gastric cancer. Use of the method and a kit when used in the method are also provided.
摘要翻译：本发明涉及一种如果患者患有癌症或患有癌症风险增加的患者的预后的方法，所述方法包括测试一种或多种与癌症相关的融合基因或其衍生的蛋白质的存在，在从患者获得的样品中。更具体地，本发明涉及胃癌中融合基因CLEC16A-EMP2，SNX2-PRDM6，MLL3-PRKAG2，DUS2L-PSKH1和CLDN18-ARHGAP26。还提供了在方法中使用该方法和试剂盒。

3. 发明申请

WO2014046619A1 GROUPING FOR CLASSIFYING GASTRIC CANCER 审中-公开
标题翻译：分组胃癌
公开(公告)号：WO2014046619A1
公开(公告)日：2014-03-27
申请号：PCT/SG2013/000409
申请日：2013-09-18
申请人： AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH , NATIONAL UNIVERSITY OF SINGAPORE
发明人： LEI, Zhengdeng , ROZEN, Steve , TAN, Patrick , SRAVANTHY, Manesh , FLOTOW, Horst , NGO, Anna
IPC分类号： C12Q1/68 , G01N33/574
CPC分类号： G06F19/24 , A61K31/513 , C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/154 , C12Q2600/156 , C12Q2600/158 , G01N33/57446 , G01N2800/52 , G01N2800/56 , G01N2800/7028 , G06F19/18 , G06F19/20
摘要： There is provided a grouping for classifying a gastric cancer tumor sample obtained from a patient suffering or suspected to suffer from gastric cancer, wherein the grouping comprises an invasive subtype, a proliferative subtype and a metabolic subtype. There is also provided a predictor and methods of using the grouping.
摘要翻译：提供了一种用于分类从患有或怀疑患有胃癌的患者获得的胃癌肿瘤样品的分组，其中所述分组包括侵入性亚型，增殖亚型和代谢亚型。还提供了使用分组的预测器和方法。

4. 发明申请

WO2019050478A1 CLEAR CELL RENAL CELL CARCINOMA BIOMARKERS 审中-公开
公开(公告)号：WO2019050478A1
公开(公告)日：2019-03-14
申请号：PCT/SG2018/050450
申请日：2018-09-05
申请人： AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH , SINGAPORE HEALTH SERVICES PTE. LTD.
发明人： YAO, Xiaosai , TAN, Patrick , TEH, Bin Tean , TAN, Jing , SHAO, Huilin , KOH, Joanna
IPC分类号： C12Q1/6886 , G01N33/574
摘要： Disclosed herein is a clear cell renal cell carcinoma (ccRCC) biomarker comprising at least 2 biomarkers selected from the group consisting of ZNF395, SMPDL3A, SLC28A1, SLC6A3, VEGFA, EGLN3, wherein at least one of the two biomarkers is SMPDL3A or SLC28A1. Also enclosed herein is a detection system using the biomarker set disclosed herein, methods of determining whether a subject has or shows recurrence of clear cell renal cell carcinoma, methods of determining whether a renal mass sample is benign or malignant, method of detecting response of a subject to systemic treatment, and a kit for carrying out the same.

5. 发明申请

WO2017142484A1 EPIGENOMIC PROFILING REVEALS THE SOMATIC PROMOTER LANDSCAPE OF PRIMARY GASTRIC ADENOCARCINOMA 审中-公开
标题翻译： EPIGENOMIC PROFILING公开了原发性胃肠道腺癌的促进剂景观
公开(公告)号：WO2017142484A1
公开(公告)日：2017-08-24
申请号：PCT/SG2017/050072
申请日：2017-02-16
申请人： AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
发明人： TAN, Patrick , QAMRA, Aditi , XING, Manjie , OOI, Wen Fong
IPC分类号： G01N33/68 , G01N33/574 , C12Q1/68 , C12N15/113 , A61P35/00
CPC分类号： G01N33/6875 , C12Q1/68 , C12Q1/6886 , G01N33/57484
摘要： The present invention relates to a method for determining the presence or absence of at least one promoter or cancer associated promoter, or a method for cancer prognosis, each based on the isolation of a nucleic acid having signal ratio of H3K4me3 to H3K4me1 greater than 1 and detecting the change in signal intensity of H3K4me3 in the nucleic acid in the cancerous biological sample relative to the non-cancerous biological sample. A biomarker for cancer detection comprising a promoter having the change in signal intensity of H3K4me3 in the cancerous biological sample relative to a non-cancerous biological sample is also disclosed herein. In a separate invention, a method for modulating the activity of at least one cancer-associated promoter or a method for modulating the immune response is further disclosed, each involving an administered inhibitor of EZH2.
摘要翻译：本发明涉及用于确定至少一种启动子或癌症相关启动子的存在或不存在的方法或用于癌症预后的方法，每种方法基于具有信号比率的核酸的分离的H3K4me3与H3K4me1的比大于1，并且检测癌性生物样品中的核酸中H3K4me3相对于非癌性生物样品的信号强度的变化。本文还公开了用于癌症检测的生物标志物，其包含相对于非癌性生物样品具有癌性生物样品中H3K4me3的信号强度变化的启动子。在单独的发明中，进一步公开了调节至少一种癌症相关启动子的活性的方法或调节免疫应答的方法，每种方法涉及施用的EZH2抑制剂。

6. 发明申请

WO2012074490A1 CONTROL OF BACTERIAL GROWTH 审中-公开
标题翻译：控制细菌生长
公开(公告)号：WO2012074490A1
公开(公告)日：2012-06-07
申请号：PCT/SG2011/000421
申请日：2011-11-29
申请人： AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH , KREISBERG, Jason , TAN, Patrick
发明人： KREISBERG, Jason , TAN, Patrick
IPC分类号： A01N41/02 , A61K31/18 , A61P31/00
CPC分类号： A01N47/36 , A61K31/18 , A61K31/505 , A61K31/506 , A61K31/53 , Y02A50/47 , Y02A50/471
摘要： The present invention provides for the use of a sulfonylamide compound or a derivative thereof in the preparation of a medicament for treating and preventing infections caused by bacteria, in which the bacteria are selected from the group consisting of bacteria having a type II enzyme acetohydroxy acid synthase and bacteria having a type III enzyme acetohydroxy acid synthase. The invention further provides the corresponding sulfonylamide compounds or derivatives thereof.
摘要翻译：本发明提供磺酰胺化合物或其衍生物在制备用于治疗和预防由细菌引起的感染的药物中的用途，其中细菌选自具有II型乙酰羟酸合酶的细菌和具有III型酶乙酰羟酸合酶的细菌。本发明还提供相应的磺酰胺化合物或其衍生物。

7. 发明申请

WO2017142485A1 CANCER EPIGENETIC PROFILING 审中-公开
标题翻译：癌症特征分析
公开(公告)号：WO2017142485A1
公开(公告)日：2017-08-24
申请号：PCT/SG2017/050073
申请日：2017-02-16
申请人： AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
发明人： TAN, Patrick , OOI, Wen Fong
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/154
摘要： The present invention relates to a method for determining the presence or absence of at least one super-enhancer in a cancerous biological sample based on signal intensity of the histone modification H3K27ac. The present invention also relates to a method for determining the prognosis of cancer in a subject, a method of determining the susceptibility of a subject to cancer or a gastrointestinal disease and a method of predicting cancer cell survival or cancer cell viability by determining the presence or absence of at least one super-enhancer. The present invention also relates to inhibitors of CDX2 and/or HNF4α, such as metformin, and use thereof for modulating the activity of a super-enhancer.
摘要翻译：本发明涉及基于组蛋白修饰H3K27ac的信号强度确定癌性生物样品中是否存在至少一种超增强子的方法。本发明还涉及用于确定受试者中癌症预后的方法，确定受试者对癌症或胃肠疾病的易感性的方法以及通过确定受试者的存在或预测癌细胞存活或癌细胞活力的方法至少缺少一个超级增强器。本发明还涉及CDX2和/或HNF4α的抑制剂，例如二甲双胍，及其用于调节超增强剂活性的用途。

8. 发明申请

WO2013002733A1 PHARMACEUTICAL COMPOSITIONS FOR TREATING CANCER 审中-公开
标题翻译：用于治疗癌症的药物组合物
公开(公告)号：WO2013002733A1
公开(公告)日：2013-01-03
申请号：PCT/SG2012/000232
申请日：2012-06-28
申请人： NATIONAL UNIVERSITY OF SINGAPORE , SINGAPORE HEALTH SERVICES PTE LTD , TAN, Patrick , IVANOVA, Tatiana
发明人： TAN, Patrick , IVANOVA, Tatiana
IPC分类号： A61K38/18 , A61K31/282 , A61K31/7105 , A61K31/711 , A61K48/00 , A61P35/00
CPC分类号： C12N15/1136 , A61K31/282 , A61K31/555 , A61K31/7105 , A61K31/711 , A61K33/24 , A61K45/06 , C12Q1/6886 , C12Q2600/136 , A61K2300/00
摘要： The present invention relates to a pharmaceutical composition comprising an anti-cancer drug and an inhibitor of bone morphogenetic protein 4 (BMP-4) or its gene expression. The present invention also relates to methods of treating cancer and prognostic methods.
摘要翻译：本发明涉及包含抗癌药物和骨形态发生蛋白4（BMP-4）抑制剂或其基因表达的药物组合物。本发明还涉及治疗癌症和预后方法的方法。

9. 发明申请

WO2012108843A1 TREATING CANCER BY INHIBITING EXPRESSION OF OLFM4, SP5, TOBI, ARJDIA, FBNI OR HAT1 审中-公开
标题翻译：通过抑制OLFM4，SP5，TOBI，ARJDIA，FBNI或HAT1的表达来治疗癌症
公开(公告)号：WO2012108843A1
公开(公告)日：2012-08-16
申请号：PCT/SG2012/000040
申请日：2012-02-13
申请人： NATIONAL UNIVERSITY OF SINGAPORE , SINGAPORE HEALTH SERVICES PTE LTD , TAN, Patrick , OH, Hue Kian
发明人： TAN, Patrick , OH, Hue Kian
IPC分类号： A61K48/00 , C12N15/113 , A61P35/00
CPC分类号： A61K31/713 , A61K31/7088 , A61K31/7105 , A61K31/712 , A61K31/7125 , C12N15/113 , C12Q1/6886 , C12N2310/141 , C12N2330/10
摘要： The present invention in one aspect relates to a method for treating cancer or enhancing a cancer treatment, the method comprising inhibiting the expression of an oligonucleotide encoding for a protein selected from the group consisting of OLFM4, SP5, TOB1, ARID1A, FBN1 and HAT1, by administering to a mammal in need of cancer treatment an effective amount of at least one silencing oligonucleotide comprising a binding motif for binding to the oligonucleotide encoding for a protein.
摘要翻译：本发明在一个方面涉及一种治疗癌症或增强癌症治疗的方法，所述方法包括抑制编码选自由OLFM4，SP5，TOB1，ARID1A，FBN1和HAT1组成的组的蛋白质的寡核苷酸的表达，通过向需要癌症治疗的哺乳动物施用有效量的至少一种沉默寡核苷酸，其包含用于结合编码蛋白质的寡核苷酸的结合基序。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式